Garetosmab, activin A inhibitor antibody for muscle-preservation combination regimens in obesity Recent Highlights: In June 2026, the company announced it would present new clinical data from the Phase 2 COURAGE trial that examines the effects of trevogrumab (anti-GDF8) on lean mass in people with obesity treated with semaglutide
aleniglipron Structure Therapeutics is testing this small-molecule oral GLP-1
These systems often use biocompatible polymers like polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), sodium alginate, or gelatin, and may include functional components such as egg-derived proteins or silk fibroin to mimic biological properties and enhance mechanical strength and drug stability [40]
For many people, the body slowly adapts over time, and symptoms become less frequent or disappear completely after several weeks
Over-the-counter interventions can provide symptomatic relief
These drugs are available as a daily or weekly injection or a daily pill